| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/31/2003 | US20030144210 Treatment of neurologic and psychiatric disorders |
| 07/31/2003 | US20030144207 Hydrophilic conjugate having a peptide that is capable of passing the blood-brain barrier covalently linked to a water-soluble nonpeptidic polymer |
| 07/31/2003 | US20030144206 Combined use of a GLP-1 compound and modulator of diabetic late complications |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144199 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 07/31/2003 | US20030144176 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 07/31/2003 | US20030143737 Long-term cell-culture compositions and genetically modified animals derived therefrom |
| 07/31/2003 | US20030143692 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143588 Phosphodiesterases |
| 07/31/2003 | US20030143304 Human and animal nutrition and dietary supplementation |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143269 Tamper-resistant oral opioid agonist formulations |
| 07/31/2003 | US20030143257 For controlled release of the drug |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143209 For gene therapy of cancers or cardiovascular conditions |
| 07/31/2003 | US20030143207 Remodeling of tissues and organ |
| 07/31/2003 | US20030143197 Administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal |
| 07/31/2003 | US20030143185 Polymer conjugates of protein kinase C inhibitors |
| 07/31/2003 | CA2514088A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | CA2511238A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | CA2476984A1 Lactoferrin as an agent for enhancing action of an opioid |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2473884A1 Method of treatment of a patient requiring analgesia |
| 07/31/2003 | CA2473796A1 Substituted quinazolin-4-ylamine analogues |
| 07/31/2003 | CA2473781A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | CA2473545A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2473536A1 Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/31/2003 | CA2473510A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 07/31/2003 | CA2473490A1 Peptide-carrying bodies for immune response |
| 07/31/2003 | CA2473395A1 Phospholipid bodies and use thereof in medical treatment |
| 07/31/2003 | CA2472835A1 Fused bicyclic pyrimidine derivatives |
| 07/31/2003 | CA2472729A1 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 07/31/2003 | CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | CA2472367A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2471989A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 07/31/2003 | CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/31/2003 | CA2454358A1 Multimeric proteins and methods of making and using same |
| 07/31/2003 | CA2452545A1 West nile vaccine comprising live attenuated, inactivated or killed whole or subunit west nile virus |
| 07/30/2003 | EP1331269A1 Novel protein, process for producing the same and use thereof |
| 07/30/2003 | EP1331010A1 Preventives and remedies for central nervous system diseases |
| 07/30/2003 | EP1330548A2 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 07/30/2003 | EP1330528A2 Regulation of human serine-threonine protein kinase |
| 07/30/2003 | EP1330468A1 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids |
| 07/30/2003 | EP1330467A2 Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| 07/30/2003 | EP1330460A2 Benzoxazinone derivatives, their preparation and use |
| 07/30/2003 | EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 07/30/2003 | EP1330451A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators |
| 07/30/2003 | EP1330448A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 07/30/2003 | EP1330442A1 Phthalazinone derivatives |
| 07/30/2003 | EP1330436A1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3-3 receptor antagonists |
| 07/30/2003 | EP1330430A2 Integrin receptor inhibitors |
| 07/30/2003 | EP1330429A2 Alkynyl amides and their therapeutic applications |
| 07/30/2003 | EP1330428A1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 07/30/2003 | EP1330427A1 Crystalline forms of venlafaxine hydrochloride |
| 07/30/2003 | EP1330426A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 07/30/2003 | EP1330293A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 07/30/2003 | EP1330267A1 Olfactory neuron cultures and method of making and using the same |
| 07/30/2003 | EP1330255A2 Use of a preparation of cimicifuga racemosa |
| 07/30/2003 | EP1330249A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 07/30/2003 | EP1330248A2 New treatments for restless legs syndrome |
| 07/30/2003 | EP1330244A1 Compositions comprising modafinil compounds |
| 07/30/2003 | EP1330240A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 07/30/2003 | EP1330233A1 Method of treating stroke |
| 07/30/2003 | EP1330166A1 Food grade transglutaminase inhibitor and uses thereof |
| 07/30/2003 | EP1233960B1 Polymorphic salt of an anti-migraine drug |
| 07/30/2003 | EP1082962B1 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors nf-(k)b |
| 07/30/2003 | EP1075256B1 Arylhydrocarbon receptor ligand antagonists |
| 07/30/2003 | EP1052989B1 Use of 2-amino-6- trifluoromehthoxy- benzothiazole for preventing or treating cerebellum dysfunction |
| 07/30/2003 | EP1011679B1 Use of 8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders |
| 07/30/2003 | EP0966286B1 Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain |
| 07/30/2003 | EP0956292A4 Conantokins |
| 07/30/2003 | EP0946541B1 Quinolines and their therapeutic use |
| 07/30/2003 | EP0942780B1 Coated particles, methods of making and using |
| 07/30/2003 | EP0935461B1 Adamantane amine derivatives for the treatment of viruses of the bornaviridae family |
| 07/30/2003 | EP0785793B1 Allosteric modulators of the nmda receptor |
| 07/30/2003 | EP0705100B1 Therapeutic substituted guanidines |
| 07/30/2003 | CN1433424A 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 07/30/2003 | CN1433418A Agents for improving learning or memory |
| 07/30/2003 | CN1433417A Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| 07/30/2003 | CN1433414A Benzazole derivatives and their use as JNK modulators |
| 07/30/2003 | CN1433412A Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 07/30/2003 | CN1433411A Chemical compounds |
| 07/30/2003 | CN1433408A Aminothiazole inhibitors of cyslin dependent kinases |
| 07/30/2003 | CN1433407A Bis-arylsulfones |
| 07/30/2003 | CN1433396A Pharmaceutical compounds |
| 07/30/2003 | CN1433321A Vaccine for prevention and treatment of Alzhermer's and amyloid related diseases |
| 07/30/2003 | CN1433318A Vascular endothelial growth factor-2 |
| 07/30/2003 | CN1433313A Combination of serotonin reuptake inhibitor and 5-HT2C antagonist, inverse agonist or partial agonist |
| 07/30/2003 | CN1433311A Methods for making sustained release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 07/30/2003 | CN1433306A Anticonvulsant derivatives useful in treating essential tremor |
| 07/30/2003 | CN1433304A Compositions for promoting sleep |
| 07/30/2003 | CN1433303A Use of fumaric acid derivatives for treating mitochondrial diseases |
| 07/30/2003 | CN1432379A Medicine for abandaning drug habits |
| 07/30/2003 | CN1432360A Application of pyrazoly anthracenone compound in prepn of medicine for preventing and treating retrogressive neuropathy |
| 07/30/2003 | CN1116304C Organic compound |